Overview

Alimta Plus Gemcitabine for Advanced Sarcoma

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
In patients with unresectable soft tissue sarcoma, what is the response rate if treated with Alimta and gemcitabine?
Phase:
Phase 2
Details
Lead Sponsor:
Columbia University
Treatments:
Gemcitabine
Pemetrexed